Physician profile
Ofer Jacobowitz
NPI 1285617381
$140,795.34
in general payments reported to CMS, 2019-2025
28 companies · $49K in 2025
The $49K reported for 2025 was more than what 99% of Sleep Medicine (Otolaryngology) providers received nationally (typical 2025 total: $509).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,630 · 2020: $20K · 2021: $401 · 2022: $49K · 2023: $744 · 2024: $15K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $51K · Consulting Fee: $12K · Food and Beverage: $2,643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,700.00 |
| Consulting Fee | $11,700.00 |
| Food and Beverage | $2,642.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $115,226.45 | 2019-2025 | Thn Sleep Therapy |
| Aerin Medical INC. | $21,677.79 | 2019-2025 | |
| Optinose US, INC. | $555.17 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $525.65 | 2019-2025 | |
| Genzyme Corporation | $370.01 | 2019-2025 | |
| Somnomed INC. | $353.25 | 2024 | |
| Acclarent, INC | $280.86 | 2019-2023 | Trudi Nav Cable |
| Glaxosmithkline, LLC. | $228.92 | 2020-2023 | Nucala |
| Inspire Medical Systems, INC. | $192.19 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $186.38 | 2021-2025 | Tezspire |
| Itamar Medical INC | $157.06 | 2021-2025 | Watchpatone |
| Harmony Biosciences LLC | $138.16 | 2022-2025 | Wakix |
| Kaleo, INC. | $117.82 | 2019-2024 | Auvi-Q |
| Stryker Corporation | $115.15 | 2019-2025 | Xpress Loprofile |
| Hikma Pharmaceuticals USA | $106.59 | 2023-2024 | Ryaltris |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $80.02 | 2025 | Zepbound |
| Alk-Abello, INC | $75.09 | 2019-2020 | |
| 3b Medical, INC. | $69.92 | 2024-2025 | Luna |
| Phathom Pharmaceuticals, INC. | $69.45 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $49.31 | 2021-2022 | |
| Zoll Respicardia, INC. | $38.82 | 2025 | Remede System |
| Intersect Ent, INC. | $38.03 | 2019 | |
| Amgen INC. | $32.68 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $31.67 | 2020 | |
| Resmed Corp | $23.14 | 2023 | |
| Circassia INC. | $19.73 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.70 | 2025 | |
| Cook Medical LLC | $16.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ofer Jacobowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.